Limits...
BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study.

Funk GC, Kirchheiner K, Burghuber OC, Hartl S - Respir. Res. (2009)

Bottom Line: The degree of lung function impairment does not sufficiently explain anxiety and depression.The BODE index was superior to FEV(1%predicted) for explaining anxious and depressive symptoms.Depressive symptoms were explained by both dyspnoea and reduced exercise capacity.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Chronic Obstructive Pulmonary Disease, Otto Wagner Hospital, Vienna, Austria. georg-christian.funk@wienkav.at

ABSTRACT

Background: Anxiety and depression are common and treatable risk factors for re-hospitalisation and death in patients with COPD. The degree of lung function impairment does not sufficiently explain anxiety and depression. The BODE index allows a functional classification of COPD beyond FEV1. The aim of this cross-sectional study was (1) to test whether the BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms; and (2) to assess which components of the BODE index are associated with these psychological aspects of COPD.

Methods: COPD was classified according to the GOLD stages based on FEV(1%predicted) in 122 stable patients with COPD. An additional four stage classification was constructed based on the quartiles of the BODE index. The hospital anxiety and depression scale was used to assess anxious and depressive symptoms.

Results: The overall prevalence of anxious and depressive symptoms was 49% and 52%, respectively. The prevalence of anxious symptoms increased with increasing BODE stages but not with increasing GOLD stages. The prevalence of depressive symptoms increased with both increasing GOLD and BODE stages. The BODE index was superior to FEV(1%predicted) for explaining anxious and depressive symptoms. Anxious symptoms were explained by dyspnoea. Depressive symptoms were explained by both dyspnoea and reduced exercise capacity.

Conclusion: The BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms in COPD patients. These psychological consequences of the disease may play a role in future classification systems of COPD.

Show MeSH

Related in: MedlinePlus

Prevalence of anxious and depressive symptoms in patients with COPD classified according to quartiles of the BODE index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2626579&req=5

Figure 2: Prevalence of anxious and depressive symptoms in patients with COPD classified according to quartiles of the BODE index.

Mentions: The anxiety score and the depression score correlated closer with the BODE index (Kτ = 0.20, p = 0.001; Kτ = 0.41, p < 0.001; respectively) than with FEV1%predicted (Kτ = -0.13, p = 0.037; Kτ = -0.28, p < 0.001; respectively). The prevalence of anxiety increased with increasing BODE stage (χ2 = 9.38, p = 0.002) but not with increasing GOLD stages (χ2 = 3.29, p = 0.070). The prevalence of depression increased with both increasing GOLD and BODE stages (χ2 = 20.47, p < 0.001; χ2 = 32.84, p < 0.001). The prevalences of anxious and depressive symptoms within the GOLD and BODE stages are shown in Figures 1 and 2.


BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study.

Funk GC, Kirchheiner K, Burghuber OC, Hartl S - Respir. Res. (2009)

Prevalence of anxious and depressive symptoms in patients with COPD classified according to quartiles of the BODE index.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2626579&req=5

Figure 2: Prevalence of anxious and depressive symptoms in patients with COPD classified according to quartiles of the BODE index.
Mentions: The anxiety score and the depression score correlated closer with the BODE index (Kτ = 0.20, p = 0.001; Kτ = 0.41, p < 0.001; respectively) than with FEV1%predicted (Kτ = -0.13, p = 0.037; Kτ = -0.28, p < 0.001; respectively). The prevalence of anxiety increased with increasing BODE stage (χ2 = 9.38, p = 0.002) but not with increasing GOLD stages (χ2 = 3.29, p = 0.070). The prevalence of depression increased with both increasing GOLD and BODE stages (χ2 = 20.47, p < 0.001; χ2 = 32.84, p < 0.001). The prevalences of anxious and depressive symptoms within the GOLD and BODE stages are shown in Figures 1 and 2.

Bottom Line: The degree of lung function impairment does not sufficiently explain anxiety and depression.The BODE index was superior to FEV(1%predicted) for explaining anxious and depressive symptoms.Depressive symptoms were explained by both dyspnoea and reduced exercise capacity.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for Chronic Obstructive Pulmonary Disease, Otto Wagner Hospital, Vienna, Austria. georg-christian.funk@wienkav.at

ABSTRACT

Background: Anxiety and depression are common and treatable risk factors for re-hospitalisation and death in patients with COPD. The degree of lung function impairment does not sufficiently explain anxiety and depression. The BODE index allows a functional classification of COPD beyond FEV1. The aim of this cross-sectional study was (1) to test whether the BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms; and (2) to assess which components of the BODE index are associated with these psychological aspects of COPD.

Methods: COPD was classified according to the GOLD stages based on FEV(1%predicted) in 122 stable patients with COPD. An additional four stage classification was constructed based on the quartiles of the BODE index. The hospital anxiety and depression scale was used to assess anxious and depressive symptoms.

Results: The overall prevalence of anxious and depressive symptoms was 49% and 52%, respectively. The prevalence of anxious symptoms increased with increasing BODE stages but not with increasing GOLD stages. The prevalence of depressive symptoms increased with both increasing GOLD and BODE stages. The BODE index was superior to FEV(1%predicted) for explaining anxious and depressive symptoms. Anxious symptoms were explained by dyspnoea. Depressive symptoms were explained by both dyspnoea and reduced exercise capacity.

Conclusion: The BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms in COPD patients. These psychological consequences of the disease may play a role in future classification systems of COPD.

Show MeSH
Related in: MedlinePlus